Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MGNX MacroGenics	$3.96 -1.2%	$3.68	$1.18 ▼ $4.64	$254.89M	1.18	790,404 shs	513,188 shs
SRZN Surrozen	$23.39 +0.1%	$27.91	$8.00 ▼ $35.00	$271.33M	0.51	91,569 shs	71,099 shs
TRDA Entrada Therapeutics	$6.46 +2.4%	$9.83	$4.93 ▼ $16.45	$244.96M	-0.26	306,416 shs	185,971 shs
UPXI Upexi	$0.91 +1.2%	$1.22	$0.54 ▼ $12.35	$63.18M	-0.35	2.37 million shs	1.62 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MGNX MacroGenics	+3.62%	-5.65%	+13.92%	+33.67%	+134.50%
SRZN Surrozen	+7.35%	-4.14%	-23.78%	-7.30%	+159.67%
TRDA Entrada Therapeutics	+5.70%	-9.86%	-11.38%	-50.28%	-20.13%
UPXI Upexi	+4.56%	-11.84%	-33.39%	-18.99%	-92.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MGNX MacroGenics	$3.96 -1.2%	$3.68	$1.18 ▼ $4.64	$254.89M	1.18	790,404 shs	513,188 shs
SRZN Surrozen	$23.39 +0.1%	$27.91	$8.00 ▼ $35.00	$271.33M	0.51	91,569 shs	71,099 shs
TRDA Entrada Therapeutics	$6.46 +2.4%	$9.83	$4.93 ▼ $16.45	$244.96M	-0.26	306,416 shs	185,971 shs
UPXI Upexi	$0.91 +1.2%	$1.22	$0.54 ▼ $12.35	$63.18M	-0.35	2.37 million shs	1.62 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MGNX MacroGenics	+3.62%	-5.65%	+13.92%	+33.67%	+134.50%
SRZN Surrozen	+7.35%	-4.14%	-23.78%	-7.30%	+159.67%
TRDA Entrada Therapeutics	+5.70%	-9.86%	-11.38%	-50.28%	-20.13%
UPXI Upexi	+4.56%	-11.84%	-33.39%	-18.99%	-92.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MGNX MacroGenics	2.29	Hold	$5.50	39.21% Upside
SRZN Surrozen	2.80	Moderate Buy	$42.00	79.75% Upside
TRDA Entrada Therapeutics	2.33	Hold	$17.50	171.53% Upside
UPXI Upexi	2.67	Moderate Buy	$8.33	814.75% Upside

Current Analyst Ratings Breakdown

Latest UPXI, SRZN, MGNX, and TRDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/8/2026	UPXI Upexi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/8/2026	TRDA Entrada Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$20.00 ➝ $17.00
5/22/2026	UPXI Upexi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/11/2026	UPXI Upexi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/8/2026	MGNX MacroGenics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/8/2026	TRDA Entrada Therapeutics	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$10.00
5/8/2026	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/7/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00 ➝ $44.00
4/21/2026	SRZN Surrozen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
4/21/2026	SRZN Surrozen	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
4/20/2026	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00

(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MGNX MacroGenics	$157.08M	1.60	N/A	N/A	$0.88 per share	4.49
SRZN Surrozen	$7.49M	36.20	N/A	N/A	($19.21) per share	-1.22
TRDA Entrada Therapeutics	$5.74M	43.60	N/A	N/A	$8.01 per share	0.80
UPXI Upexi	$26.14M	2.45	N/A	N/A	$1.01 per share	0.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MGNX MacroGenics	-$74.62M	-$1.10	N/A	N/A	N/A	-44.79%	-147.80%	-28.40%	8/13/2026 (Estimated)
SRZN Surrozen	-$242.03M	-$37.59	N/A	N/A	N/A	-4,810.50%	-4,055.04%	-154.08%	8/14/2026 (Estimated)
TRDA Entrada Therapeutics	-$143.75M	-$3.99	N/A	N/A	N/A	-2,895.05%	-51.22%	-42.20%	8/5/2026 (Estimated)
UPXI Upexi	-$13.68M	-$0.62	N/A	N/A	N/A	-874.00%	-66.70%	-19.56%	N/A

Latest UPXI, SRZN, MGNX, and TRDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2026	Q1 2026	MGNX MacroGenics	-$0.57	-$0.58	-$0.01	-$0.58	$15.24 million	$20.78 million
5/12/2026	Q3 2026	UPXI Upexi	-$0.20	-$1.67	-$1.47	-$1.67	$2.90 million	$1.05 million
5/7/2026	Q1 2026	TRDA Entrada Therapeutics	-$1.06	-$0.95	+$0.11	-$0.95	$2.92 million	$0.88 million
5/6/2026	Q1 2026	SRZN Surrozen	-$1.0920	-$11.65	-$10.5580	-$11.65	$4.00 million	$5.00 million
3/23/2026	Q4 2025	SRZN Surrozen	-$1.2875	-$7.59	-$6.3025	-$23.88	$0.66 million	$0.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MGNX MacroGenics	N/A	1.90	1.80
SRZN Surrozen	N/A	11.91	11.91
TRDA Entrada Therapeutics	N/A	13.90	13.90
UPXI Upexi	2.96	1.72	1.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MGNX MacroGenics	96.89%
SRZN Surrozen	66.57%
TRDA Entrada Therapeutics	86.39%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
MGNX MacroGenics	13.60%
SRZN Surrozen	31.74%
TRDA Entrada Therapeutics	9.49%
UPXI Upexi	9.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MGNX MacroGenics	430	63.56 million	54.92 million	Optionable
SRZN Surrozen	80	11.61 million	7.93 million	Not Optionable
TRDA Entrada Therapeutics	110	38.82 million	35.14 million	Optionable
UPXI Upexi	130	70.26 million	63.94 million	Optionable

UPXI, SRZN, MGNX, and TRDA Headlines

Recent News About These Companies

UPXI Share News Today

May 19, 2026 | uk.investing.com

Upexi (UPXI) Stock Forecast & Price Target

May 15, 2026 | investing.com

Upexi Stock Short Interest Report | NASDAQ:UPXI | Benzinga

May 15, 2026 | benzinga.com

Upexi (UPXI) Q3 2026 Earnings Transcript

May 15, 2026 | fool.com

Upexi, Inc. Earnings Call Highlights Crypto-Fueled Volatility

May 13, 2026 | tipranks.com

Upexi Net Loss Balloons to $109 Million on Solana Treasury Markdown

May 13, 2026 | finance.yahoo.com

Upexi Reports Fiscal Third Quarter 2026 Financial Results

May 12, 2026 | globenewswire.com

Upexi Q3 2026 earnings preview

May 11, 2026 | msn.com

Upexi to Present at the LD Micro Invitational XVI Conference on May 17-19

May 7, 2026 | globenewswire.com

Upexi Provides Periodic Update to its Share Repurchase Program

May 6, 2026 | globenewswire.com

Upexi to Host Third Quarter 2026 Earnings Call on May 12th at 5:30 p.m. ET

May 5, 2026 | globenewswire.com

Upexi to Participate in the Scottsdale Capital Event on April 10-12

March 31, 2026 | globenewswire.com

Upexi to Participate in Upcoming March Investor Conferences

March 3, 2026 | globenewswire.com

Upexi Earnings Call: Growth Surges, Losses Mount

February 15, 2026 | tipranks.com

Insiders' US$4.22m Investments In Red Following Upexi's US$18m Dip In Market Value

February 14, 2026 | finance.yahoo.com

Upexi Inc (UPXI) Q2 2026 Earnings Call Highlights: Revenue Soars Amid Digital Asset Challenges

February 13, 2026 | uk.finance.yahoo.com

Upexi Inc (UPXI) Q2 2026 Earnings Call Highlights: Revenue Soars Amid Digital Asset Challenges

February 13, 2026 | uk.finance.yahoo.com

Upexi, Inc. (NASDAQ: UPXI) Q2 2026 earnings call transcript

February 11, 2026 | msn.com

Upexi (UPXI) Q2 2026 Earnings Call Transcript

February 11, 2026 | finance.yahoo.com

Upexi targets yield growth and capital market innovation amid Solana-driven volatility

February 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI, SRZN, MGNX, and TRDA Company Descriptions

MacroGenics NASDAQ:MGNX

$3.96 -0.05 (-1.25%)

Closing price 04:00 PM Eastern

Extended Trading

$3.93 -0.03 (-0.86%)

As of 04:27 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Surrozen NASDAQ:SRZN

$23.39 +0.02 (+0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$23.40 +0.02 (+0.06%)

As of 04:23 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Entrada Therapeutics NASDAQ:TRDA

$6.46 +0.15 (+2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$6.45 -0.01 (-0.15%)

As of 04:10 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Upexi NASDAQ:UPXI

$0.91 +0.01 (+1.22%)

Closing price 04:00 PM Eastern

Extended Trading

$0.92 +0.01 (+1.52%)

As of 07:57 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UPXI, SRZN, MGNX, and TRDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UPXI, SRZN, MGNX, and TRDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UPXI, SRZN, MGNX, and TRDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI, SRZN, MGNX, and TRDA Company Descriptions

MacroGenics NASDAQ:MGNX

Surrozen NASDAQ:SRZN

Entrada Therapeutics NASDAQ:TRDA

Upexi NASDAQ:UPXI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UPXI, SRZN, MGNX, and TRDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UPXI, SRZN, MGNX, and TRDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UPXI, SRZN, MGNX, and TRDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI, SRZN, MGNX, and TRDA Company Descriptions

MacroGenics NASDAQ:MGNX

Surrozen NASDAQ:SRZN

Entrada Therapeutics NASDAQ:TRDA

Upexi NASDAQ:UPXI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools